Priti Hegde, Global Head of Research at Kite Pharma, shared on LinkedIn:
“I hope you will join me at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting in Phoenix, AZ, November 4-8, 2026.
This is an incredibly exciting time in drug discovery and development. We are witnessing an unprecedented diversification of therapeutic platforms, giving us powerful new ways to address complex biology and accelerate innovation for patients.
We are developing an engaging pre-conference workshop that will feature early clinical insights from a broad spectrum of modalities, including ex vivo CAR-T therapies, in vivo CAR-T approaches, tumor-infiltrating lymphocyte (TIL) therapies, T-cell engagers, bispecific antibodies, and antibody-drug conjugates (ADCs). Together, these programs highlight the growing translatability of well-founded preclinical differentiation hypotheses into meaningful clinical outcomes.
Beyond the workshop, SITC remains one of the most energizing meetings of the year, bringing together leaders across research and development to share breakthrough science, discuss emerging clinical data, build new collaborations, and celebrate the progress being made in immunotherapy. I look forward to seeing many of you there, including at The CheckPoints Party!
If you haven’t had a chance to register.”